Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Gilteritinib for FLT+ R/R AML

Giovanni Martinelli • 26 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia Gilteritinib

Giovanni Martinelli, MD, University in Bologna, Bologna, Italy, discusses the use of gilteritinib for FLT+ R/R acute myeloid leukemia (AML). This interview was recorded at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Giovanni Martinelli

1:42
CAR-T updates in AML and ALL
Giovanni Martinelli • 7 Dec 2019
1:01
Giovanni Martinelli: exciting CAR-T research
Giovanni Martinelli • 25 Oct 2019
1:36
Blinatumomab for R/R Ph+ AML
Giovanni Martinelli • 25 Oct 2019
1:12
How will we pave the way to transplant for high risk patients?
Giovanni Martinelli • 25 Oct 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals